buy updat durat repotrectinib
messag report financi result line expect
posit pipelin updat includ track design updat data
lead product repotrectinib non-smal cell lung cancer nsclc updat
durat respons dor data small patient popul highlight profil
look competit rel competitor inhibitor xalkori rozlytrek
rog-sw impact modest far minor impact clinic trial
enrol compani remain on-track preclin clinic trial
updat line prior guidanc maintain buy pt
lead product repotrectinib obtain track design tki-naiv lung cancer
patient updat efficaci exce month median progression-fre
surviv mpf recal repotrectinib previous obtain track design
updat repotrectinib includ investigator-assess month median durat
respons mdor month mpf tki-naiv patient remain
therapi month data cutoff though earli limit
patient number result includ patient initi dose view
competit compar xalkori month mdor rog-sw rozlytrek
month mdor brain metastas month mdor brain metastas
though earli repotrectinib promis activ brain metastas could
potenti anoth differenti rozlytrek intracrani respons rate
respons durat rang month patient
on-going recal rozlytrek previous report mdor
mpf month month respect patient baselin
modest far potenti increment impact clinic trial enrol
speed compani taken step mitig impact work
irb activ site remot allow patient undergo routin test
closer home monitor trial particip via video confer howev
mention experienc delay site activ subsequ enrol
overal impact depend pandem durat sever clinic trial suppli remain
said registr phase ii studi remain on-track read earli
interim data patient across cohort potenti alreadi
activ approxim half clinic trial site across
countri includ major us key site europ asia expect
enrol patient across cohort registr exploratori provid
updat phase ii patient approxim quantiti patient
phase portion
earli pipelin product on-track near-term preclin
initi clinic data beyond conduct phase i/ii studi
repotrectinib pediatr patient inhibitor ret/src
inhibitor remain on-track read phase safeti along earli
 initi efficaci data amplif patient incy/novn-sw
gener inhibitor remain on-track undergo ind submiss earli
recal preclin data suggest low-nanomolar potenc
wild-typ solvent-front mutat resist xalkori alunbrig
jp alecensa rog-sw zykadia novn-sw well compound mutat
page analyst certif import disclosur
resist lorbrena preclin data
repotrectinib combin present see preview
planner aacr virtual confer june
updat estim account result maintain buy pt
end cash invest updat near-term
estim account oper expens includ modif stock
vest pursuant compani transit agreement scientif founder former chief
page analyst certif import disclosur
valu per share use dcf analysi use wacc consist clinical-
stage biotech compani cover proof-of-concept data well termin growth rate risk includ regulatori
commerci setback potenti emerg new competitor lower product sale expect dilut financ beyond
assum
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc sec file
page analyst certif import disclosur
